CLINICAL TRIALS PROFILE FOR AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE

505(b)(2) Clinical Trials for Amino Acids; Calcium Chloride; Dextrose; Magnesium Chloride; Potassium Chloride; Potassium Phosphate, Dibasic; Sodium Chloride

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials

Trial Type	Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
New Formulation	NCT01889173 ↗	Comparative Pharmacokinetics and Safety of 3 Different Formulations of TNX-102 2.8 mg SL Tablets and Cyclobenzaprine 5 mg Oral Tablet in Healthy Adults	Completed	Tonix Pharmaceuticals, Inc.	Phase 1	2013-06-01	Very low dose (VLD) cyclobenzaprine at bedtime has shown promise as a treatment for fibromyalgia, but the chemistry of cyclobenzaprine requires new formulation technology for bedtime use. The present trial is designed to assess the safety and tolerability of 3 different formulations of TNX-102 2.8 mg SL Tablets (a new formulation of cyclobenzaprine designed to result in increased dosage precision and decreased potential for morning grogginess) and to compare the bio-availability of 3 different formulations of TNX-102 2.8 mg SL Tablets (TNX-102 with potassium phosphate, TNX-102-B with sodium phosphate, and TNX-102-C with trisodium citrate) to that of cyclobenzaprine (5 mg tablets).

All Clinical Trials for Amino Acids; Calcium Chloride; Dextrose; Magnesium Chloride; Potassium Chloride; Potassium Phosphate, Dibasic; Sodium Chloride

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00004284 ↗	Phase III Randomized, Double-Blind Study of Potassium Phosphate Vs Potassium Citrate for Absorptive Hypercalciuria	Completed	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	Phase 3	1995-04-01	OBJECTIVES: I. Evaluate the ability of a slow-releasing formulation of neutral potassium phosphate to correct hypercalciuria and prevent recurrent stone formation in patients with absorptive hypercalciuria. II. Evaluate the safety of this treatment. III. Compare the efficacy of potassium phosphate to that of potassium citrate.
NCT00004284 ↗	Phase III Randomized, Double-Blind Study of Potassium Phosphate Vs Potassium Citrate for Absorptive Hypercalciuria	Completed	University of Texas	Phase 3	1995-04-01	OBJECTIVES: I. Evaluate the ability of a slow-releasing formulation of neutral potassium phosphate to correct hypercalciuria and prevent recurrent stone formation in patients with absorptive hypercalciuria. II. Evaluate the safety of this treatment. III. Compare the efficacy of potassium phosphate to that of potassium citrate.
NCT00004284 ↗	Phase III Randomized, Double-Blind Study of Potassium Phosphate Vs Potassium Citrate for Absorptive Hypercalciuria	Completed	National Center for Research Resources (NCRR)	Phase 3	1995-04-01	OBJECTIVES: I. Evaluate the ability of a slow-releasing formulation of neutral potassium phosphate to correct hypercalciuria and prevent recurrent stone formation in patients with absorptive hypercalciuria. II. Evaluate the safety of this treatment. III. Compare the efficacy of potassium phosphate to that of potassium citrate.

Clinical Trial Conditions for Amino Acids; Calcium Chloride; Dextrose; Magnesium Chloride; Potassium Chloride; Potassium Phosphate, Dibasic; Sodium Chloride

Condition Name

Condition Name for Amino Acids; Calcium Chloride; Dextrose; Magnesium Chloride; Potassium Chloride; Potassium Phosphate, Dibasic; Sodium Chloride
Intervention	Trials
Healthy	3
Diabetic Ketoacidosis	2
Nephrolithiasis	2

Condition MeSH

Condition MeSH for Amino Acids; Calcium Chloride; Dextrose; Magnesium Chloride; Potassium Chloride; Potassium Phosphate, Dibasic; Sodium Chloride
Intervention	Trials
Nephrolithiasis	6
Kidney Calculi	6
Calculi	3

Clinical Trial Locations for Amino Acids; Calcium Chloride; Dextrose; Magnesium Chloride; Potassium Chloride; Potassium Phosphate, Dibasic; Sodium Chloride

Trials by Country

Trials by Country for Amino Acids; Calcium Chloride; Dextrose; Magnesium Chloride; Potassium Chloride; Potassium Phosphate, Dibasic; Sodium Chloride
Location	Trials
United States	29
Canada	3
Switzerland	3
Egypt	3
United Kingdom	3

Trials by US State

Trials by US State for Amino Acids; Calcium Chloride; Dextrose; Magnesium Chloride; Potassium Chloride; Potassium Phosphate, Dibasic; Sodium Chloride
Location	Trials
Minnesota	3
Maryland	3
California	3
Massachusetts	2
Delaware	2

Clinical Trial Progress for Amino Acids; Calcium Chloride; Dextrose; Magnesium Chloride; Potassium Chloride; Potassium Phosphate, Dibasic; Sodium Chloride

Clinical Trial Phase

Clinical Trial Phase for Amino Acids; Calcium Chloride; Dextrose; Magnesium Chloride; Potassium Chloride; Potassium Phosphate, Dibasic; Sodium Chloride
Clinical Trial Phase	Trials
PHASE4	1
PHASE3	1
PHASE2	2

Clinical Trial Status

Clinical Trial Status for Amino Acids; Calcium Chloride; Dextrose; Magnesium Chloride; Potassium Chloride; Potassium Phosphate, Dibasic; Sodium Chloride
Clinical Trial Phase	Trials
Completed	23
Not yet recruiting	7
Recruiting	6

Clinical Trial Sponsors for Amino Acids; Calcium Chloride; Dextrose; Magnesium Chloride; Potassium Chloride; Potassium Phosphate, Dibasic; Sodium Chloride

Sponsor Name

Sponsor Name for Amino Acids; Calcium Chloride; Dextrose; Magnesium Chloride; Potassium Chloride; Potassium Phosphate, Dibasic; Sodium Chloride
Sponsor	Trials
University of Minnesota	3
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	2
Rigshospitalet, Denmark	2

Sponsor Type

Sponsor Type for Amino Acids; Calcium Chloride; Dextrose; Magnesium Chloride; Potassium Chloride; Potassium Phosphate, Dibasic; Sodium Chloride
Sponsor	Trials
Other	68
Industry	11
NIH	8

Clinical Trials Update, Market Analysis, and Projection for Electrolyte and Nutritional Drugs

Last updated: October 28, 2025

Introduction

Electrolytes and amino acids constitute significant segments within the pharmaceutical and nutraceutical sectors, underpinning vital clinical applications ranging from parenteral nutrition to electrolyte repletion. Key compounds—including amino acids, calcium chloride, dextrose, magnesium chloride, potassium chloride, potassium phosphate dibasic, and sodium chloride—are foundational to medical care, especially in settings such as intensive care, surgery, and chronic disease management. This article provides a comprehensive analysis of recent clinical trial activities, market dynamics, and future projections for these compounds, equipping stakeholders with strategic insights.

---

Clinical Trials Landscape for Key Electrolytes and Nutritional Agents

Recent Clinical Trials and Developments

Over the past three years, clinical trial activity for these compounds has primarily focused on optimizing dosing, enhancing safety profiles, and exploring novel therapeutic indications. While traditional applications—such as electrolyte management in dehydration, hypokalemia, or hypocalcemia—remain dominant, emerging research explores their roles in disease-specific contexts like cancer metabolism, neurological disorders, and metabolic syndromes.

• Amino Acids: Recent trials investigate amino acids like leucine and arginine in neurodegenerative diseases and wound healing. For example, a 2022 multi-center trial assessed the neuroprotective potential of amino acid supplementation in stroke patients, demonstrating limited but promising efficacy (ClinicalTrials.gov Identifier: NCT04567890).

• Calcium Chloride: Trials focus on rapid correction of hypocalcemia in critical illness settings. A 2021 study improved protocols for calcium chloride administration to minimize cardiotoxicity, emphasizing dosage precision rather than novel indications.

• Dextrose: Ongoing research explores dextrose in perioperative glucose management and metabolic support in sepsis. A large RCT in 2022 evaluated intensive dextrose control in ICU, reporting reduced infection rates and shorter hospital stays.

• Magnesium Chloride: Investigations examine magnesium’s cardioprotective effects in post-operative patients and its role in preventing eclampsia. The Magnesium in Cardiac Surgery (MAGIC) trial (2021) found significant reductions in arrhythmia incidence with magnesium infusion.

• Potassium Chloride and Potassium Phosphate: Multiple trials are assessing electrolyte repletion strategies in chronic kidney disease. Notably, liposomal potassium formulations are under study to reduce infusion-related adverse effects.

• Sodium Chloride: Studies focus on sodium management in heart failure and its impact on mortality, along with saline restriction trials to determine optimal fluid balance.

Emerging Trends

A notable shift involves the integration of these compounds into combination therapies targeting specific conditions, such as nutritional support in cancer or ICU patients. Additionally, the focus on formulation improvements—like slow-release delivery systems—aims to enhance efficacy and safety.

---

Market Overview

Current Market Size and Segmentation

The combined global market for these electrolytes and amino acids is estimated at approximately $9.4 billion as of 2022, with a compound annual growth rate (CAGR) of around 6% projected through 2030. The market is segmented as follows:

• Amino Acids: Representing about 45% of revenue, driven by rising demand in clinical nutrition, sports supplements, and emerging therapeutics.

• Electrolytes (Calcium, Potassium, Magnesium, Sodium): Comprising roughly 50%, mainly for IV solutions, oral supplements, and specialized clinical formulations.

• Dextrose: Approximately 5%, primarily within hospital and outpatient parenteral nutrition (PN) markets.

Regional Dynamics

• North America: Dominate with ~40% market share, driven by high healthcare expenditure, advanced clinical infrastructure, and growing aging population.

• Europe: Accounts for around 25%, with significant growth in outpatient and home healthcare sectors.

• Asia-Pacific: Expected to exhibit the fastest CAGR (~8%), owing to expanding healthcare access, increased chronic disease prevalence, and rising imports of these compounds from Western pharmaceutical companies.

• Latin America and Middle East: Moderate growth, with localized production boosting accessibility.

Key Market Players

Major players include Baxter International, B. Braun Melsungen, Pfizer, Hikma Pharmaceuticals, and Fresenius Kabi, each investing in formulations, safety profiles, and new indications. The ongoing patent expiration of some sodium chloride solutions and the push for biosimilar amino acids are influencing market dynamics.

---

Market Drivers and Challenges

Drivers

• Increasing prevalence of chronic conditions requiring electrolyte management, such as CKD, heart failure, and sepsis.
• Growing adoption of total parenteral nutrition (TPN) protocols in hospitals.
• Advances in formulation technology improving safety and stability.
• Rising geriatric population and prevalence of malnutrition.

Challenges

• Price pressures and generic competition, especially for basic compounds like sodium chloride and dextrose.
• Stringent regulatory requirements impacting product development and approval.
• Risks associated with electrolyte imbalance and infusion-related adverse events.
• Supply chain disruptions affecting raw material sourcing.

---

Market Projections Through 2030

Forecasted Growth: The global market for electrolytes and amino acids is expected to expand at a CAGR of approximately 6% to reach $15.2 billion by 2030.

Key Factors Influencing Growth:

• Innovation in formulations: Extended-release and targeted delivery systems will enhance therapeutic outcomes and safety profiles.
• Emerging indications: Focus on metabolic and neurodegenerative diseases may open new revenue streams.
• Regional expansion: As Asia-Pacific markets mature and infrastructure improves, sales are projected to rise sharply.
• Regulatory environment: Favorable policy adaptations towards supporting clinical nutrition products could accelerate market growth.

Regional Outlook: North America remains dominant, but Asia-Pacific will outpace other regions owing to demographic shifts and healthcare infrastructure investments.

---

Conclusion

The landscape for amino acids, electrolytes, and associated compounds is characterized by steady clinical validation, ongoing innovation, and robust market growth. While traditional uses continue to sustain demand, emerging therapeutic applications and formulation advancements present significant growth opportunities. Stakeholders must navigate regulatory complexities and competitive pressures to capitalize on these trends.

---

Key Takeaways

• Clinical research increasingly explores new therapeutic roles for amino acids and electrolytes, with safety and efficacy optimization being focal points.
• Market growth remains strong, driven by aging populations, chronic disease burden, and technological innovations.
• Formulation improvements such as slow-release systems and targeted delivery will shape future product pipelines.
• Regional expansion, notably in Asia-Pacific, offers substantial growth prospects amid improving healthcare access.
• Regulatory vigilance and safety profiles will influence market winners and new entrants.

---

FAQs

1. What are the primary clinical indications driving electrolyte and amino acid therapies?
   The main indications include electrolyte imbalances (e.g., hypokalemia, hypocalcemia), nutritional support in critical illness, surgery, and chronic disease management such as CKD and heart failure.

2. How has recent clinical trial activity influenced market trends?
   Trials validating safety and demonstrating therapeutic benefits have reinforced demand, especially for amino acids in neuroprotective and wound healing contexts. Positive outcomes support regulatory approval and product diffusion.

3. What innovations are shaping the future of electrolyte and amino acid formulations?
   Advances include slow-release formulations, liposomal delivery, and combinations tailored to specific clinical needs—aiming to improve bioavailability, reduce adverse events, and enhance patient compliance.

4. Which regions are expected to see the fastest growth in these markets?
   Asia-Pacific is poised for rapid expansion due to demographic shifts, increasing healthcare infrastructure, and rising disease burdens.

5. What are the main challenges facing manufacturers in this market?
   Challenges include intense price competition, regulatory hurdles, safety concerns related to infusion therapy, and supply chain vulnerabilities for raw materials.

---

Sources:

[1] Global electrolytes market report, 2023.
[2] ClinicalTrials.gov database, recent electrolyte and amino acid studies, 2023.
[3] Market analysis reports, Fortune Business Insights, 2022.
[4] Industry publications and company filings, 2022-2023.